Unlocking the full potential of digital endpoints for decision making: a novel modular evidence concept enabling re-use and advancing collaboration-Reference-Cited by-同舟云学术

Unlocking the full potential of digital endpoints for decision making: a novel modular evidence concept enabling re-use and advancing collaboration

Published:2024-05-15 Issue:6 Volume:24 Page:731-741
ISSN:1473-7167
Container-title:Expert Review of Pharmacoeconomics & Outcomes Research
language:en
Short-container-title:Expert Review of Pharmacoeconomics & Outcomes Research

Author:

Leyens Lada¹²,Batchelor John¹,De Beuckelaer Erwin³,Langel Kai⁴,Hartog Bert⁵

Affiliation:

1. Regulatory Science, DEEP Measures Oy, Helsinki, Finland

2. Product Development Regulatory, F. Hoffmann-La Roche Ltd, Basel, Switzerland

3. Quality, Janssen Pharmaceutica N.V, Beerse, Belgium

4. Regulatory, Janssen Cilag S.A, Madrid, Spain

5. Clinical Operations and Innovation, Janssen-Cilag B.V, DS Breda, The Netherlands

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737167.2024.2334347

Reference66 articles.

1. Accelerating Adoption of Patient-Facing Technologies in Clinical Trials: A Pharmaceutical Industry Perspective on Opportunities and Challenges

2. National Academies of Sciences, Engineering, and Medicine; Health and Medicine; Division; Board on Health Sciences Policy; Roundtable on Genomics and Precision Health; Forum on Drug Discovery, Development, and Translation.The Role of Digital Health Technologies in Drug Development: Proceedings of a Workshop. Shore C, SH B, Nicholson A, Addie S, Hackmann M, Khandekar E, editors. Washington (DC): National Academies Press (US); 2020 Aug 28. PMID: 32870622.

3. Illuminating the dark spaces of healthcare with ambient intelligence

4. European regulators’ views on a wearable-derived performance measurement of ambulation for Duchenne muscular dystrophy regulatory trials

5. Mapping Relevance of Digital Measures to Meaningful Symptoms and Impacts in Early Parkinson’s Disease